Physician profile
Moses T Laffitte
NPI 1316917388
$1,841.29
in general payments reported to CMS, 2019-2025
32 companies · $88.05 in 2025
The $88.05 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $109 · 2022: $426 · 2023: $298 · 2024: $165 · 2025: $88.05.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $425.45 | 2019-2024 | |
| Duchesnay USA Incorporated | $186.72 | 2019 | |
| Astellas Pharma US INC | $152.05 | 2019-2024 | Veozah |
| Daiichi Sankyo INC. | $122.15 | 2019-2025 | Injectafer |
| Pfizer INC. | $107.88 | 2019-2022 | |
| Exeltis, USA INC. | $93.25 | 2023-2025 | Slynd |
| Therapeuticsmd, INC. | $86.02 | 2019-2022 | |
| Novo Nordisk INC | $75.12 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.17 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $62.83 | 2022-2024 | |
| Sage Therapeutics, LLC | $53.79 | 2024-2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $50.13 | 2019-2020 | |
| Myovant Sciences INC. | $40.36 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.78 | 2022 | |
| Dexcom, INC. | $27.83 | 2023 | Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $26.32 | 2019-2023 | Paragard T 380a |
| Amgen INC. | $25.31 | 2019 | |
| Mylan Pharmaceuticals INC. | $21.24 | 2022 | |
| Vertical Pharmaceuticals, LLC | $15.62 | 2019 | |
| Evofem Biosciences, INC. | $14.89 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.61 | 2022 | |
| Exact Sciences Corporation | $14.57 | 2024 | Cologuard Collection Kit |
| Agile Therapeutics, INC. | $14.13 | 2024 | Twirla |
| Millicent US INC | $13.82 | 2020 | |
| Mission Pharmacal Company | $12.07 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.75 | 2019 | |
| Avion Pharmaceuticals | $11.41 | 2020 | |
| Meditrina | $11.25 | 2023 | |
| Allergan, INC. | $10.90 | 2019 | |
| Coloplast Corp | $10.82 | 2019 | |
| Organon LLC | $8.94 | 2024 | |
| Channel Medsystems, INC. | $7.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moses Laffitte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.